Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fish Oil and FADS1 in Colorectal Cancer Prevention
NCT01661764Phase 2Completed
- Sponsor
- Vanderbilt University
- Start
- Feb 2013
- Primary completion
- Dec 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of eicosapentaenoic acid + docosahexaenoic acid in colorectal cancer (CRC) (6 arms), sponsored by Vanderbilt University. Primary endpoints: Rectal Epithelial Cell Proliferation at 6 months and Rectal Epithelial Cell Apoptosis at 6 months. Started Feb 2013; status: completed.
02
Drugs
eicosapentaenoic acid + docosahexaenoic acid
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT01661764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01661764.